Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965861 · ClinicalTrials.gov registry record
SCRI Tissue Testing Registry
A clinical trial, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- 20
- Enrollment target
NCT00965861 is a clinical trial that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 20 participants.
The verdict
NCT00965861 was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.
Interventions
- OTHER Tissue Registry Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00965861
The ClinicalTrials.gov registry entry for NCT00965861 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tissue Registry Study is the first listed.
NCT00965861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00965861 about?
NCT00965861 is a clinical study titled "SCRI Tissue Testing Registry". Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a fut...
What is the current status of trial NCT00965861?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2010-05. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00965861?
The interventions under investigation include: Tissue Registry Study (OTHER).
Who is sponsoring clinical trial NCT00965861?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.